{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:53:20Z","timestamp":1791402800222,"version":"4.3.3"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"\n Background<\/jats:title>\n \n Helicobacter pylori<\/jats:italic>\n (\n H. pylori<\/jats:italic>\n ) eradication has been reported to cause short-term disruption of gut microbiota. It is acknowledged that probiotics supplementation mitigates side effects induced by\n H. pylori<\/jats:italic>\n eradication, yet its role on alleviating dysbiosis of microbiota is obscure.\n <\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To evaluate the impact of probiotics on gastrointestinal microbiota after eradication therapy.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This was a multicenter, double-blinded, randomized trial done at seven centers in China. A total of 276 treatment-na\u00efve\n H. pylori<\/jats:italic>\n -positive patients were randomly assigned to receive 14-day bismuth-containing quadruple therapy (esomeprazole, bismuth, amoxicillin, furazolidone) combined with probiotics (Bifidobacterium Tetragenous viable Bacteria Tablets) (n=140) or placebo (n=136) for 28 days. Saliva, gastric mucosa and fecal samples were collected before and after therapy for 16S rRNA gene sequencing.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The incidence of gastrointestinal adverse events was lower in probiotics group compared to placebo group (23.6% vs 37.7%, p=0.016), while there was no significant difference in eradication rate. We found dramatic perturbations of gut microbiota immediately following eradication, with the predominance of Proteobacteria in replacement of commensal Firmicutes and Bacteroidetes, and gradually restored after two weeks. The reduction of gut Bacteroidetes caused by eradication drugs was neutralized with probiotics supplementation. The gastric microbiota was completely reconstituted with\n H. pylori<\/jats:italic>\n depleted and other taxa flourished. Of note, patients treated with probiotics showed smaller fluctuations of gastric microbiota compared to those with placebo. We also observed changes of saliva microbiota after\n H. pylori<\/jats:italic>\n eradication, illustrated by the overgrowth of\n Neisseria<\/jats:italic>\n and depletion of\n Streptococcus<\/jats:italic>\n . The expansion of some pathogenic genera, including\n Porphyromonas<\/jats:italic>\n ,\n Leptotrichia<\/jats:italic>\n , in the mouth was suppressed by probiotics.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n This study not only demonstrated the beneficial effect of probiotics implementation on side events during\n H. pylori<\/jats:italic>\n eradication but also provided a comprehensive profile of microbiome alterations along gastrointestinal tract that modulated by probiotics.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fimmu.2022.1033063","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:56:27Z","timestamp":1667868987000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":74,"title":["Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Cong","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijuan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonghua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322368","article-title":"Screening and eradication of helicobacter pylori for gastric cancer prevention: The Taipei global consensus","volume":"69","author":"Liou","year":"2020","journal-title":"Gut"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14947","article-title":"Consensus on eradication of helicobacter pylori and prevention and control of gastric cancer in China (2019, shanghai)","volume":"35","author":"Du","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of helicobacter pylori infection-the maastricht V\/Florence consensus report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"B4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto consensus for the treatment of helicobacter pylori infection in adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12713","article-title":"Changes in the human gut microbiota composition caused by helicobacter pylori eradication therapy: A systematic review and meta-analysis","volume":"25","author":"Ye","year":"2020","journal-title":"Helicobacter"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12809","article-title":"Long-term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for helicobacter pylori eradication in Chinese children","volume":"26","author":"Zhou","year":"2021","journal-title":"Helicobacter"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30272-5","article-title":"Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after helicobacter pylori eradication: a multicentre, open-label, randomised trial","volume":"19","author":"Liou","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12754","article-title":"Helicobacter pylori infection and eradication: Exploring their impacts on the gastrointestinal microbiota","volume":"25","author":"Tao","year":"2020","journal-title":"Helicobacter"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfda.2018.12.011","article-title":"Next generation probiotics in disease amelioration","volume":"27","author":"Chang","year":"2019","journal-title":"J Food Drug Anal"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.776955","article-title":"Saccharomyces boulardii combined with quadruple therapy for helicobacter pylori eradication decreased the duration and severity of diarrhea: A multi-center prospective randomized controlled trial","volume":"8","author":"Zhao","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00333-2","article-title":"Effect of bacillus clausii capsules in reducing adverse effects associated with helicobacter pylori eradication therapy: A randomized, double-blind, controlled trial","volume":"9","author":"Plomer","year":"2020","journal-title":"Infect Dis Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12856","article-title":"Effects of non-viable lactobacillus reuteri combining with 14-day standard triple therapy on helicobacter pylori eradication: A randomized double-blind placebo-controlled trial","volume":"26","author":"Yang","year":"2021","journal-title":"Helicobacter"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00372-9","article-title":"The effect of probiotics supplementation on gut microbiota after helicobacter pylori eradication: A multicenter randomized controlled trial","volume":"10","author":"Tang","year":"2021","journal-title":"Infect Dis Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12848","article-title":"The impact of helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults","volume":"26","author":"Yuan","year":"2021","journal-title":"Helicobacter"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7150\/jca.29072","article-title":"A randomised trial of probiotics to reduce severity of physiological and microbial disorders induced by partial gastrectomy for patients with gastric cancer","volume":"10","author":"Zheng","year":"2019","journal-title":"J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00073","article-title":"Oral probiotics alleviate intestinal dysbacteriosis for people receiving bowel preparation","volume":"7","author":"Deng","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2017.04.004","article-title":"Probiotics in helicobacter pylori eradication therapy: Systematic review and network meta-analysis","volume":"41","author":"Wang","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0209-9","article-title":"Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2","volume":"37","author":"Bolyen","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319696","article-title":"Effect of helicobacter pylori on gastrointestinal microbiota: a population-based study in linqu, a high-risk area of gastric cancer","volume":"69","author":"Guo","year":"2020","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto Global consensus report on helicobacter pylori gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325630","article-title":"Chinese Consensus report on family-based helicobacter pylori infection control and management (2021 edition)","volume":"71","author":"Ding","year":"2022","journal-title":"Gut"},{"key":"B22","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3390\/nu14030632","article-title":"A four-probiotics regimen combined with a standard helicobacter pylori-eradication treatment reduces side effects and increases eradication rates","volume":"14","author":"Viazis","year":"2022","journal-title":"Nutrients"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00372-9","article-title":"The effect of probiotics supplementation on gut microbiota after helicobacter pylori eradication: A multicenter randomized controlled trial","volume":"10","author":"Tang","year":"2020","journal-title":"Infect Dis Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodres.2018.08.088","article-title":"Investigations of bacteroides spp. towards next-generation probiotics","volume":"116","author":"Tan","year":"2019","journal-title":"Food Res Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/apt.15650","article-title":"Systematic review: Gastric microbiota in health and disease","volume":"51","author":"Rajilic-Stojanovic","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2017-000144","article-title":"Alteration in the gastric microbiota and its restoration by probiotics in patients with functional dyspepsia","volume":"4","author":"Igarashi","year":"2017","journal-title":"BMJ Open Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12903-020-01070-1","article-title":"Analysis of by high-throughput sequencing: Helicobacter pylori infection and salivary microbiome","volume":"20","author":"Ji","year":"2020","journal-title":"BMC Oral Health"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/00220345211064571","article-title":"Pathways linking oral bacteria, nitric oxide metabolism, and health","volume":"101","author":"Morou-Bermudez","year":"2022","journal-title":"J Dent Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.01.146","article-title":"Human oral microbiota and its modulation for oral health","volume":"99","author":"Zhang","year":"2018","journal-title":"BioMed Pharmacother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1033063\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:56:34Z","timestamp":1667868994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1033063\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2022.1033063"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1033063","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"article-number":"1033063"}}